LFCR at a glance
LIFECORE BIOMEDICAL, INC. DE (LFCR, SEC CIK 1005286) filed its latest 10-K annual report on August 7, 2025, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as June 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended May 25, 2025 (FY2025), LIFECORE BIOMEDICAL, INC. DE (LFCR) reported revenue of $128.9 million (up 0.5% from FY2024) and a net loss of $38.7 million. Diluted EPS was -$1.27.
- As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding LIFECORE BIOMEDICAL, INC. DE (LFCR) shares worth $39.3 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $128.9M
- +0.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 20 funds
- $39.3M · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $25.3M, down 19% YoY from $31.1M
- Gross margin 27.0% vs 25.0% YoY, gross profit $6.8M vs $7.8M
- CDMO largest segment at $17.8M, down 18%; HA manufacturing weakest decline, down 19% to $7.5M
- Cash $23.0M, operating cash flow $9.5M, revolving facility undrawn with $15.0M available
- Outlook: liquidity sufficient for at least 12 months, Series A redemption obligation $51.1M due December 28, 2026
Risk Factors
- New merger risk: closing depends on HSR Act clearance, with the waiting period scheduled to expire November 9, 2026
- Most material update: Alcon relationship risk, Alcon represented 52% of nine-month revenue and must maintain specified agreements
- Regulatory risk: additional governmental approval conditions could delay or prevent closing, or impose costs and operating limitations
- Operational risk: merger uncertainty could disrupt CDMO customer relationships and key personnel retention
- Financial risk: termination could require a $9,957,716 fee and leave debt maturing May 22, 2029
AI summary of the LFCR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- DOJ and FTC early termination of HSR waiting period effective November 4, 2026, clearing the antitrust condition
- Merger remains pending, with Company stockholder approval and other closing conditions outstanding
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month fiscal 2026 financial results announced for periods ended September 30, 2026
- Results press release furnished as Exhibit 99.1, providing the substantive financial details
Item EX-99.1: Item EX-99.1
- Q3 revenue $25.3M, down 18.6%; nine-month revenue $82.7M, down 21.8%, signaling continued demand weakness
- CDMO revenue fell 18% in Q3 and 29% year-to-date, the primary driver of sales deterioration
Item 8.01: Other Events
- Special meeting set for November 4, 2026, to vote on adoption of the merger agreement and proposed merger
- November 4, 2026 record date determines stockholder voting eligibility
AI summaries of LFCR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LFCR
Don't miss the next LFCR filing
- Alerts as it files. A push when LFCR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LFCR, by share count.
- Ask anything. An AI agent that reads every LFCR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| OBUS NELSON | A | Jun 4, 2026 | 25,907 | - |
| Kiper Christopher S | A | Jun 4, 2026 | 25,907 | - |
| Antunes Humberto Calheiros | A | Jun 4, 2026 | 25,907 | - |
| Johnson Paul Harold | A | Jun 4, 2026 | 25,907 | - |
| Korenberg Matthew E | A | Jun 4, 2026 | 25,907 | - |
| Schechter Joshua | A | Jun 4, 2026 | 25,907 | - |
| HOUDE LOVAS KATRINA | A | Jun 4, 2026 | 25,907 | - |
| Aryeh Jason | A | Jun 4, 2026 | 25,907 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $128.3M | $128.9M |
| Gross Profit | - | $41.9M | $40.3M |
| Operating Income | - | -$8.8M | -$17.2M |
| Net Income | - | $12.0M | -$38.7M |
| Gross Margin | - | 32.6% | 31.3% |
| Op. Margin | - | -6.9% | -13.4% |
| Net Margin | - | 9.4% | -30.0% |
| Balance Sheet | |||
| Total Assets | $253.5M | $254.0M | $239.3M |
| Equity | - | $11.3M | $1.3M |
| ROE | - | 106.2% | -2898.0% |
| Per Share | |||
| EPS | $-3.32 | $0.32 | $-1.27 |
| Cash Flow | |||
| Operating CF | - | -$217K | -$206K |
| CapEx | - | $18.4M | $13.4M |
Source: XBRL data in LIFECORE BIOMEDICAL, INC. DE (LFCR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LFCR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 20 | $39.3M |
| Q2 2026 | 21 | $31.0M |
| Q1 2026 | 19 | $20.4M |
| Q4 2025 | 21 | $47.6M |
| Q3 2025 | 19 | $39.7M |
| Q2 2025 | 20 | $46.2M |
| Q1 2025 | 16 | $23.2M |
| Q4 2024 | 11 | $20.8M |
- Citadel Advisors LLC+186.3K (+188%)
- Renaissance Technologies LLC+58.1K (+55%)
- BlackRock+5.1K (+0%)
- Vanguard Portfolio Management LLC+4.5K (+2%)
- Bank of America Corp+2.9K (+8%)
- Millennium Management−70.8K (-53%)
- Morgan Stanley−31.8K (-4%)
- State Street Corp−29.9K (-4%)
- AQR Capital Management−19.3K (-35%)
- Wells Fargo & Co−18.1K (-76%)
- FMR LLC (Fidelity)−10.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 147 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LFCR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 20, 2026 | - | Analysis | - |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 29, 2026 | - | - | |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 16, 2026 | - | - | - |
| 8-K | Mar 16, 2026 | - | Analysis | - |
| 8-K | Mar 5, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
LFCR SEC filings: frequently asked questions
Which institutions hold LFCR stock?
As of September 30, 2026, the largest LIFECORE BIOMEDICAL, INC. DE (LFCR) holders among the 13F filers tracked by SignalX were BlackRock ($13.3 million), Vanguard Capital Management LLC ($8.5 million), Morgan Stanley ($4.9 million), State Street Corp ($4.2 million), Citadel Advisors LLC ($1.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LFCR's revenue in fiscal year 2025?
For the fiscal year ended May 25, 2025 (FY2025), LIFECORE BIOMEDICAL, INC. DE (LFCR) reported revenue of $128.9 million (up 0.5% from FY2024) and a net loss of $38.7 million. Diluted EPS was -$1.27. The figures come from the XBRL data in the 10-K.
What did LFCR report in its latest 8-K?
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed an 8-K on November 5, 2026 reporting Item 8.01 (Other Events). DOJ and FTC early termination of HSR waiting period effective November 4, 2026, clearing the antitrust condition.
What are the latest LFCR SEC filings?
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed its latest 10-K annual report on August 7, 2025, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on June 8, 2026.
What is LFCR's SEC CIK number?
LIFECORE BIOMEDICAL, INC. DE (LFCR)'s SEC Central Index Key (CIK) is 1005286. EDGAR lists every LFCR filing under that number.
Ask anything about LFCR
The research agent reads LFCR's filings, financials, insider trades and 13F holders, then answers with sources.